Akademik Veri Yönetim Sistemi
Bioinformatics and Computational Biology Conference, Naples, İtalya, 27 - 29 Kasım 2024, ss.1-5
ntroduction: Recent developments in metabolomics have highlighted the intricate nature of fatty acid metabolism in health and disease. As a crucial class of metabolites, changes in free fatty acid (FFA) levels are significantly involved in the development and progression of various diseases. The aim of this study was to perform quantification of serum fatty acid levels in Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients and to compare them according to clinical outcomes of disease progression (slow and rapid progression), development of hypertension (present/absent) and mortality (ex and survived). Methods: Plasma samples for metabolomic analysis were collected from 254 patients diagnosed with ADPKD at the Nephrology Clinic of Erciyes University Faculty of Medicine. These patients were being actively monitored during the study period. The serum amino acid profiles were analyzed using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Results: No differences were observed in fatty acid metabolic profiles between patients with rapid progression of ADPKD and those with slower disease progression. However, significant differences in LysoPE(0:0/18:2(9Z,12Z)) and PE(14:1(9Z)/16:1(9Z)) profiles were observed between mortality groups. In addition, significant differences were found in the levels of LysoPC(0:0/18:0), LysoPE(0:0/18:0), LysoPE(0:0/18:3(6Z,9Z,12Z)), and LysoPE(0:0/20:0) between patients with hypertension and those without hypertension. These metabolic alterations are strongly associated with the underlying molecular mechanisms of ADPKD. Additionally, statistically significant correlations were found between specific fatty acid levels. Conclusion: The findings of this study emphasize the therapeutic potential of fatty acid metabolism in ADPKD and underline the prognostic value of fatty acids in these diseases.